Acknowledgement to Referees
- PDF / 129,642 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 92 Downloads / 154 Views
ACKNOWLEDGEMENT TO REFEREES
Acknowledgement to Referees
Published online: 8 November 2017 # Springer International Publishing AG, part of Springer Nature 2017
Dear Reader, As we reach the final issue of Targeted Oncology for 2017, I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content over the past 12 months. In 2017, 70 articles have been published in Targeted Oncology; the most popular of these, in terms of downloads from SpringerLink (as of October 2017), have been: Florczuk M., Szpechcinski A., Chorostowska-Wynimko J. miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. Targeted Oncology (2017), 12(2):179-200. Rosen L.S., Jacobs I.A., Burkes R.L. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology (2017), 12(5):599-610. Kim E.S., Scott L.J. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. Targeted Oncology (2017), 12(3):373-383. Dhillon S. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma. Targeted Oncology (2017), 12(2):255-262. Gupta N., Yang H., Hanley M.J., et al. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/ Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology (2017), 12(5):643-654. Keating G.M. Sorafenib: A Review in Hepatocellular Carcinoma. Targeted Oncology (2017), 12(2):243-253. Skaltsa K., Ivanescu C., Naidoo S. et al. Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology (2017), 12(1):111-121. Bylicki O., Paleiron N., Margery J., et al. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALKTranslocated Non-Small-Cell Lung Cancer. Targeted Oncology (2017), 12(5):563-569. Corallo S., D’Argento E., Strippoli A., et al. Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase InhibitorResistant Non-Small Cell Lung Cancer. Targeted Oncology (2017), 12(2):153-161. Wise-Draper T.M., Moorthy G., Salkeni M.A., et al. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Targeted Oncology (2017), 12(3):323-332. These 10 articles alone have been downloaded almost 8,000 times all together, while all articles published in 2017 were downloaded an impressive 22,000 times (as of October 2017). The quality of articles published in the journal is also reflected in its most recent impact factor 3.438, making 2016 the fourth consecutive year with an impact factor over 3.
706
Targ Oncol (2017) 12:705–708
Other journals in the Adis Premier Journals Portfolio (http://www.springer.com/gp/adis) continue to prosper, and this year has seen the successful launch of PharmacoEconomics - Open, the newest journal in the portfolio. The journal has published a full volume of 30 arti
Data Loading...
